Quality assessment of economic evaluations in health care: A checklist and user guide;La medición de la calidad de los estudios de evaluación económica. Una propuesta de 'checklist' para la toma de decisiones

Revista Espanola de Salud Publica

Volumn 83, Issue 1, 2009, Pages 71-84

  María, José ^a   Perpinán, Abellán ^a   Sánchez, Fernando Ignacio ^a   Eduardo, Martínez Y Jorge ^a   Pérez, Martínez ^a  

^a UNIVERSITY OF MURCIA   (Spain)

Author keywords

Delphi technique; Economic; Evaluation

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE DELIVERY; PRACTICE GUIDELINE; QUALITY CONTROL;

COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; GUIDELINES AS TOPIC; QUALITY CONTROL;

EID: 67651065020     PISSN: 11355727     EISSN: 16969820     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ y Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd Edition. Oxford: Oxford University Press; 2005.
2. Del Llano J, Pinto JL y Abellán JM, editores. Eficencia y Medicamentos: Revisión de las guías de Evaluation Económica. La cuarta garantía. Madrid: Sanofi-Aventis; 2008.
3. Ministerio de Administraciones Públicas. Incidencia de las medidas adoptadas para la rationalization del gasto farmacéutico. Madrid:MAP; 2008.
4. Rodriguez-Monguio R, Anton∼zas F. Health Care Rationing in Spain: Framework, Descriptive Analysis and Consequences. Pharmaco Economics. 2006;24:537-548.
5. García-Altés A.Twenty Years of Health Care Economic Analysis in Spain: Are we Doing Well? Health Econ 2001;10: 715-719.
6. Oliva Moreno J, del Llano Sen∼arís JE y Sacristán del Castillo JA. La evaluación económica de tecnologías sanitarias en Espan∼a: situación actual y utilidad como guía en la asignación de recursos sanitarios. Información Comercial Espanola 2003; 804:155-167.
7. Anton∼anzas Villar FJ. Challenges to achieving value in drug spending in a decentralized country: the spanish case. Value Health 2003; 6 Supl 1:52-63.
8. Kristensen FB, Sigmund H, editors. Health Technology Assessment Handbook. Copenhagen: Danish Centre for Health Technology Assessment, National Board of Health; 2007.
9. Sacristán JA, Soto J y Galende l. Evaluation of pharmacoeconomic studies: utilization of a checklist, Ann Pharmacother 1993; 27: 1.126-1.133.
10. Bradley CA, Iskedjian M, Lanctot KL, Mittmann N, Simone C, St Pierre E, et al. Quality assessment of economic evaluations in selected pharmacy, medical, and health economics journals. Ann. Pharmacother 1995;29 (Pt 7): 681-689.
11. Iskedjian M, Trakas K, Bradley CA, Addis A, Lanctot K, Kruk D, et al. Quality assessment of economic evaluations published in Pharmacoeco-nomics: the first four years (1992 to 1995). Phar-macoeconomics 1997; 12:685-94.
12. Weinstein MC, Siegel JE, Gold MR, Kamlet MS y Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-1258.
13. Ofman JJ, Sullivan SD, Neumann PJ, Chiou C, Henning JM, Wade SW y Hay JW. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm 2003; 9:53-61.
14. Chiou C, Hay J, Wallace JF, Bloom BS, Neumann PJ, Sullivan SD et al. Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care 2003;41:32-44.
15. Evers S, Goossens M, de Vet H, van Tulder M y Ament A. Criteria List for Assessment of Methodological Quality of Economic Evaluations: Consensus on Health Economic Criteria. Int J Technol Assess Health Care 2005; 21(Pt 2) :240-245.
16. Anis AH, Gagnon V. Using economic evaluations to make formulary coverage decisions. So much for guidelines. Pharmacoeconomics 2000;18( Pt1): 55-62.
17. Hill SR, Mitchell AS y Henry DA. Problems with the interpretation of pharmaeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA 2000;283:2116-2121
18. Ramsberg J, Odeberg S, Engstrom A y-Douglas L. Examining the quality of health economic analyses submitted to the Pharmaceutical Benefits Board in Sweden. The first year. Eur J Health Econ 2004;49:351-356.
19. Atthobari J, Bos JM, Boersma C, Brouwers JRBJ, Jong-van den Berg LTW y Postma MJ. Adherence of Pharmacoeconomic Studies to National Guidelines in the Netherlands. Pharm World Sci 2005; 27: 364-370
20. Baladi JF, Menon D y Otten N. Use of economic evaluation guidelines: 2 years' experience in Canada. Health Econ 1998;7:221-227
21. López J, Oliva J, Anton∼anzas F, García-Altés A, Gisbert R, Mar J, Puig J. Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias. Madrid: Plan Nacional para el SNS del MSC. Servicio de Evaluacion del Servicio Cana-rio de Salud; 2008. Informes de Evaluación de Tecnologías Sanitarias: SESCS; 2006/22.
22. Antioch KM, Jennings G, Botti M, Chapman R y Wulfsohn V. Integrating cost-effectiveness evidence into clinical practice guidelines in Australia for acute myocardial infarction. Eur J Health Econom 2002; 3:26-39
23. Gold MR, Siegel JE, Russell LB y Weinstein MC, editors. Cost-effectiveness in Health and Medicine. Oxford: Oxford University Press; 1996.
24. Davis JA. Elementary survey analysis. Englewood Cliffs, NJ: Prentice-Hall; 1971.
25. Hinkle DE, Wiersma W, Jurs SG. Applied statistics for the behavioral sciences. Chicago: Rand McNally College Publishing.
26. Abellán Perpin∼án JM, Sánchez Martínez FI y Martínez Pérez JE. Evaluación económica de tec-nologías sanitarias: ¿valen lo que cuestan? Cua-dernos Económicos de ICE 2008; 75: 191-210.
27. Pinto JL, Rodríguez R. ¿Cuánto vale la pena gastarse para ganar un an∼o de vida ajustado por la calidad? Un estudio empírico. En: El valor monetario de la salud. Barcelona: Springer-Verlag; 2001. p.52-91.
28. Pinto JL, Martínez JE. Estimación del valor mone-tario de los an∼ vida ajustados por la calidad: estimaciones preliminares. Ekonomiaz 2005; 60: 192-209.
29. Center on the Evaluation of Value and Risk in Health. The Cost-Effectiveness Analysis Registry [Internet]. (Boston), Tufts-New England Medical Center, ICRHPS. Disponible en: http://www.tufts-nemc.org/cearegistry/.
30. Paul JE, Trueman P. 'Fourth hurdle reviews', NICE, and database applications. Pharmacoepide-miology and drug safety, 2001; 10: 429-438.
31. Brouwer WBF y Koopmanschap MA. On the economic foundations of CEA. Ladies and gentleman, take your positions! Journal of Health Economics 2000; 19: 439-459.
32. Keeler EB, Cretin S. Discounting of life-saving and other nonmonetary effects. Management Science 1983; 29: 300-6.
33. Welte R, Feenstra F, Jager H, Leidl R. A decision chart for assessing and improving the transferabi-lity of economic evaluation results between countries. PharmacoEconomics 2004; 22:857-876.